- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: GnRHa.
Displaying page 1 of 1.
EudraCT Number: 2020-004780-71 | Sponsor Protocol Number: PROFERTIL | Start Date*: Information not available in EudraCT |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A phase III Randomized Double-Blinded Placebo-Controlled Study of Use of GnRHa during Chemotherapy for Fertility Protection of Young Women and Teenagers with Cancer - ProFertil | ||
Medical condition: Breast Cancer Acute Leukemia Lymphomas (Hodgkin and non-Hodgkin) Sarcomas (Osteo, Soft tissue and Ewing) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-004131-61 | Sponsor Protocol Number: M16-904 | Start Date*: 2023-04-18 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45 mg 6-Month Depot Formulation in Children with Ce... | ||
Medical condition: Central Precocious Puberty | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2012-005571-14 | Sponsor Protocol Number: TIMING | Start Date*: 2013-08-02 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: CLINICAL TRIAL, SINGLE BLIND, RANDOMIZED, CONTROLLED PROSPECTIVE EVALUATION FOR OPTIMUM TIME INTERVAL BETWEEN ACETATE ADMINISTRATION AND PUNCTURE TRIPTORELIN FOLLICULAR IN IVF TREATMENT | ||
Medical condition: INFERTILITY | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004493-42 | Sponsor Protocol Number: L-CP07-167 | Start Date*: 2014-12-03 | |||||||||||
Sponsor Name:Abbvie previously known as Abbott | |||||||||||||
Full Title: A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children with Central Precocious Puberty | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000448-13 | Sponsor Protocol Number: Agonist6 | Start Date*: 2014-04-23 | |||||||||||
Sponsor Name:The Fertility Clinic, Skive Regional Hospital | |||||||||||||
Full Title: The exogenous progesterone free luteal phase after GnRHa trigger – a randomized controlled pilot study in high-responder IVF patients | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009429-26 | Sponsor Protocol Number: local 997 (P06034) | Start Date*: 2010-03-15 |
Sponsor Name:FREE UNIVERSITY OF BRUSSELS | ||
Full Title: A PILOT STUDY TO EVALUATE THE EFFECT OF TRIGGERING FINAL OOCYTE MATURATION WITH GnRHa OR hCG ON ENDOMETRIAL RECEPTIVITY PARAMETERS AND THE LUTEAL PHASE IN OOCYTE DONORS | ||
Medical condition: Compare the endometrium of oocyte donors, who had final oocyte maturation with either hCG, Suprefact, followed by hCG 35 hours after triggering, Suprefact or Suprefact without luteal phase support.... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005337-37 | Sponsor Protocol Number: ONC-2012-002 | Start Date*: 2013-05-07 | |||||||||||
Sponsor Name:Istituto Clinico Humanitas | |||||||||||||
Full Title: ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE | |||||||||||||
Medical condition: Female subjects, aged <40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim to assess the role of AMH as surrogate marker of the preservation of ovarian rese... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000447-32 | Sponsor Protocol Number: Agonist5 | Start Date*: 2014-04-23 | |||||||||||
Sponsor Name:The Fertility Clinic, Skive regional Hospital | |||||||||||||
Full Title: The exogenous progesterone free luteal phase after GnRHa trigger – a randomized controlled pilot study in normo-responder IVF patients | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004494-16 | Sponsor Protocol Number: L-CP07-177 | Start Date*: 2014-12-03 | |||||||||||
Sponsor Name:Abbvie previously known as Abbott | |||||||||||||
Full Title: A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children with Central Precocious Puberty | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003364-12 | Sponsor Protocol Number: 64091742PCR3001 | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects ... | |||||||||||||
Medical condition: Metastatic Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) FR (Trial now transitioned) NL (Completed) CZ (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005249-21 | Sponsor Protocol Number: 1239.3 | Start Date*: 2006-02-16 |
Sponsor Name:Boehringer Ingelheim Ltd. | ||
Full Title: A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer | ||
Medical condition: Chemo-naive hormone refractory prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005255-18 | Sponsor Protocol Number: 1216.19 | Start Date*: 2006-07-03 |
Sponsor Name:Boehringer Ingelheim UK Ltd | ||
Full Title: A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic... | ||
Medical condition: Advanced Metastatic Hormone Refractory Prostate Cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000212-89 | Sponsor Protocol Number: antagovo | Start Date*: 2008-03-04 |
Sponsor Name:Instituto Universitario IVI Valencia | ||
Full Title: Uso de antagonistas de la GnRH en la preparación endometrial de las receptoras de ovocitos. | ||
Medical condition: Comparar los resultados obtenidos con el empleo de antagonistas de la GnRH en la sincronización receptora de ovocitos–donante frente a los resultados obtenidos con el tradicional empleo de supresió... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002057-38 | Sponsor Protocol Number: 64091742PCR2001 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | |||||||||||||
Medical condition: mCRPC and DNA-repair anomalies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) DK (Prematurely Ended) NL (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002832-15 | Sponsor Protocol Number: 49916 | Start Date*: 2014-12-17 | |||||||||||
Sponsor Name:VU university medical center | |||||||||||||
Full Title: Ulipristal versus Gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy: a double blind randomized controlled trial | |||||||||||||
Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard which removes the fibroids entirely, preferably lapa... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003552-23 | Sponsor Protocol Number: 64091742PCR2002 | Start Date*: 2018-05-10 | ||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||
Full Title: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | ||||||||||||||||||
Medical condition: Metastatic castration-resistant prostate cancer (mCRPC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000735-32 | Sponsor Protocol Number: 56021927PCR3002 | Start Date*: 2015-09-21 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | |||||||||||||
Medical condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) RO (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004322-24 | Sponsor Protocol Number: ARN-509-003 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Aragon Pharmaceuticals, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer | |||||||||||||
Medical condition: Castration-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Ongoing) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Ongoing) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) DK (Ongoing) HU (Ongoing) CZ (Trial now transitioned) SK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005208-20 | Sponsor Protocol Number: 2019DEPO-TRIGGER001 | Start Date*: 2022-08-10 | |||||||||||
Sponsor Name:Universitair Ziekenhuis Brussel | |||||||||||||
Full Title: Depo-Trigger trial: GnRH agonist DEPOt TRIGGER for final oocyte maturation in breast cancer patients undergoing fertility preservation: a pilot study. | |||||||||||||
Medical condition: Female patients with breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001878-18 | Sponsor Protocol Number: MK8962-043 | Start Date*: 2017-07-19 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (corifollitropin alfa) in Combination with human Chorionic Gonadotropin (hCG) for Initiat... | |||||||||||||
Medical condition: Treatment of adolescent males 14 to <18 years old with HH | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) DK (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.